AI Engines For more Details: Perplexity Kagi Labs You
Energy Production: Fumarate plays a crucial role in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. This cycle is essential for the production of adenosine triphosphate (ATP), the primary energy currency of cells. By participating in the citric acid cycle, fumarate contributes to energy metabolism and cellular respiration.
Skin Conditions: Fumarate esters, such as dimethyl fumarate (DMF), have been used as a treatment for psoriasis, a chronic inflammatory skin condition characterized by red, scaly patches on the skin. DMF has been shown to have anti-inflammatory and immunomodulatory properties, which can help alleviate symptoms of psoriasis and improve skin health.
Neurological Disorders: Research suggests that fumarate derivatives, particularly dimethyl fumarate (DMF), may have neuroprotective effects and could be beneficial in the treatment of neurological disorders such as multiple sclerosis (MS). DMF has been approved as a disease-modifying therapy for relapsing forms of MS due to its anti-inflammatory and antioxidative properties, which help reduce neuroinflammation and protect nerve cells from damage.
Antioxidant Activity: Fumarate exhibits antioxidant properties, which can help neutralize free radicals and reduce oxidative stress in the body. Oxidative stress is implicated in the pathogenesis of various chronic diseases, including cardiovascular disease, neurodegenerative disorders, and cancer. By scavenging free radicals, fumarate may help protect cells from oxidative damage and support overall health.
Gastrointestinal Health: Fumarate is involved in the regulation of intestinal mucosal integrity and barrier function. It may help maintain the health of the gastrointestinal tract by supporting the integrity of the intestinal epithelium and promoting the secretion of mucin, a protective layer that lines the intestinal wall. Fumarate derivatives have been investigated for their potential therapeutic role in inflammatory bowel diseases (IBD) and other gastrointestinal disorders.
Cellular Signaling: Fumarate has been implicated in various cellular signaling pathways, including those involved in inflammation, apoptosis (programmed cell death), and cell proliferation. Dysregulation of fumarate metabolism has been associated with certain cancers and metabolic disorders. Understanding the role of fumarate in cellular signaling pathways may offer insights into disease mechanisms and potential therapeutic targets.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Increases |
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium animalis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
| species | Bifidobacterium pseudolongum | Increases |
| species | Enterococcus durans | Increases |
| species | Enterococcus faecalis | Increases |
| species | Enterococcus faecium | Increases |
| species | Faecalibacterium prausnitzii | Increases |
| species | Lactobacillus acidophilus | Increases |
| species | Lactobacillus crispatus | Increases |
| species | Lactobacillus gasseri | Increases |
| species | Lactobacillus helveticus | Increases |
| species | Lactobacillus jensenii | Increases |
| species | Lactobacillus johnsonii | Increases |
| species | Lactobacillus kefiranofaciens | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 3.2 | 2.1 | 0.52 |
| ADHD | 3 | 3.7 | -0.23 |
| Age-Related Macular Degeneration and Glaucoma | 0.9 | 0.8 | 0.13 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 0.8 | 1.25 |
| Allergies | 3.7 | 4.7 | -0.27 |
| Allergy to milk products | 1.2 | 3.5 | -1.92 |
| Alopecia (Hair Loss) | 0.7 | 1.8 | -1.57 |
| Alzheimer's disease | 8.6 | 7 | 0.23 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 4.5 | -2.75 |
| Ankylosing spondylitis | 2.2 | 2.8 | -0.27 |
| Anorexia Nervosa | 3.9 | 0.5 | 6.8 |
| Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
| Asthma | 2.5 | 2.1 | 0.19 |
| Atherosclerosis | 2.6 | 2.4 | 0.08 |
| Atrial fibrillation | 2.1 | 4.5 | -1.14 |
| Autism | 9.1 | 8.8 | 0.03 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.5 | 0.5 | |
| Biofilm | 0.4 | -0.4 | |
| Bipolar Disorder | 3.9 | 3.1 | 0.26 |
| Brain Trauma | 2.2 | 1.2 | 0.83 |
| Breast Cancer | 0.7 | -0.7 | |
| Cancer (General) | 1.9 | 1.9 | |
| Carcinoma | 3 | 3 | 0 |
| Celiac Disease | 5.2 | 2.1 | 1.48 |
| Cerebral Palsy | 2.2 | 1.2 | 0.83 |
| Chronic Fatigue Syndrome | 5 | 4.8 | 0.04 |
| Chronic Kidney Disease | 2.6 | 2.1 | 0.24 |
| Chronic Lyme | 0.6 | 0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 0.8 | 1.5 |
| Chronic Urticaria (Hives) | 2.2 | 2.2 | |
| Coagulation / Micro clot triggering bacteria | 2.6 | 2.6 | |
| Colorectal Cancer | 2.4 | 4.9 | -1.04 |
| Constipation | 1.4 | 1.1 | 0.27 |
| Coronary artery disease | 1.8 | 1.4 | 0.29 |
| COVID-19 | 9.2 | 8.6 | 0.07 |
| Crohn's Disease | 6.8 | 9.1 | -0.34 |
| cystic fibrosis | 2.1 | 0.6 | 2.5 |
| d-lactic acidosis (one form of brain fog) | 1 | -1 | |
| deep vein thrombosis | 2 | 2 | |
| Depression | 8.9 | 8.8 | 0.01 |
| Dermatomyositis | 0.6 | 2.1 | -2.5 |
| Eczema | 1.9 | 3 | -0.58 |
| Endometriosis | 2.5 | 2 | 0.25 |
| Eosinophilic Esophagitis | 0.3 | 1.9 | -5.33 |
| Epilepsy | 3.7 | 4.2 | -0.14 |
| erectile dysfunction | 0.3 | 0.8 | -1.67 |
| Fibromyalgia | 2 | 1.5 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 3.3 | 6 | -0.82 |
| gallstone disease (gsd) | 2.4 | 1.5 | 0.6 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.6 | 0.17 |
| Generalized anxiety disorder | 1.2 | 1 | 0.2 |
| giant cell arteritis | 0.3 | 0.2 | 0.5 |
| Glioblastoma | 2 | 0.5 | 3 |
| Gout | 1.1 | 1.7 | -0.55 |
| Graves' disease | 2.3 | 4 | -0.74 |
| Halitosis | 0.4 | 0.3 | 0.33 |
| Hashimoto's thyroiditis | 3 | 2.6 | 0.15 |
| Heart Failure | 0.2 | 0.2 | |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | 0.5 | -0.67 |
| Hidradenitis Suppurativa | 0.2 | 0.5 | -1.5 |
| High Histamine/low DAO | 2.3 | 1.4 | 0.64 |
| hypercholesterolemia (High Cholesterol) | 1.7 | 0.9 | 0.89 |
| hyperglycemia | 2.2 | 1.2 | 0.83 |
| Hyperlipidemia (High Blood Fats) | 2.7 | 0.8 | 2.38 |
| hypersomnia | 1.1 | 1.1 | |
| hypertension (High Blood Pressure | 7.3 | 7.3 | 0 |
| Hypothyroidism | 3.1 | 0.8 | 2.88 |
| Hypoxia | 0.5 | 0.6 | -0.2 |
| IgA nephropathy (IgAN) | 1.8 | 1.1 | 0.64 |
| Inflammatory Bowel Disease | 7.2 | 4 | 0.8 |
| Insomnia | 1.7 | 1.7 | 0 |
| Intelligence | 0.2 | 1.5 | -6.5 |
| Intracranial aneurysms | 1.2 | 1.4 | -0.17 |
| Irritable Bowel Syndrome | 4.2 | 5.2 | -0.24 |
| Juvenile idiopathic arthritis | 1.1 | -1.1 | |
| Liver Cirrhosis | 5.1 | 7.2 | -0.41 |
| Long COVID | 11.6 | 11 | 0.05 |
| Low bone mineral density | 2.1 | 1.5 | 0.4 |
| Lung Cancer | 2.7 | 0.2 | 12.5 |
| Mast Cell Issues / mastitis | 2.9 | 0.5 | 4.8 |
| ME/CFS with IBS | 2.2 | 0.6 | 2.67 |
| ME/CFS without IBS | 1.6 | 0.6 | 1.67 |
| Menopause | 0.4 | 0.4 | 0 |
| Metabolic Syndrome | 10.9 | 11.5 | -0.06 |
| Mood Disorders | 12.4 | 11.9 | 0.04 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.6 | 0.17 |
| Multiple Sclerosis | 5.9 | 3.7 | 0.59 |
| Multiple system atrophy (MSA) | 2.1 | 1.3 | 0.62 |
| myasthenia gravis | 0.6 | 0.4 | 0.5 |
| neuropathic pain | 0.4 | 0.4 | |
| Neuropathy (all types) | 2.2 | 2.9 | -0.32 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.1 | 0.36 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.8 | 1.3 | 2.69 |
| NonCeliac Gluten Sensitivity | 2.9 | 1.6 | 0.81 |
| Obesity | 7 | 6.5 | 0.08 |
| obsessive-compulsive disorder | 3.8 | 3.1 | 0.23 |
| Osteoarthritis | 1.6 | 1.1 | 0.45 |
| Osteoporosis | 1.9 | 3.5 | -0.84 |
| pancreatic cancer | 0.3 | -0.3 | |
| Parkinson's Disease | 10.2 | 6.8 | 0.5 |
| Polycystic ovary syndrome | 2.3 | 3.1 | -0.35 |
| Postural orthostatic tachycardia syndrome | 0.8 | 0.2 | 3 |
| Premenstrual dysphoric disorder | 1.4 | 1.5 | -0.07 |
| primary biliary cholangitis | 0.3 | 1 | -2.33 |
| Psoriasis | 3.5 | 3.7 | -0.06 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.5 | 9.7 | -0.29 |
| Rosacea | 1.4 | 2.9 | -1.07 |
| Schizophrenia | 5.7 | 6.7 | -0.18 |
| scoliosis | 0.6 | 1.1 | -0.83 |
| sensorineural hearing loss | 0.6 | 0.6 | |
| Sjögren syndrome | 3.9 | 1.4 | 1.79 |
| Sleep Apnea | 2.6 | 2.1 | 0.24 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.6 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 1.8 | -3.5 |
| Stress / posttraumatic stress disorder | 3.4 | 4.1 | -0.21 |
| Systemic Lupus Erythematosus | 6.4 | 2.8 | 1.29 |
| Tic Disorder | 1 | 1.5 | -0.5 |
| Tourette syndrome | 0.9 | 0.9 | |
| Type 1 Diabetes | 3.7 | 2.9 | 0.28 |
| Type 2 Diabetes | 7.3 | 8.5 | -0.16 |
| Ulcerative colitis | 7 | 5.9 | 0.19 |
| Unhealthy Ageing | 3.3 | 1.4 | 1.36 |
| Vitiligo | 1 | 2.8 | -1.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]
